Barclays
IPCI

Barclays’s Intellipharmaceuticals International Inc. IPCI Stock Holding History

Barclays’s Portfolio IPCI Stock Details IPCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,775
Closed -$5K – 7666
2018
Q3 		$5K Sell
1,775
-1,051
-37% -$3.51K ﹤0.01% 6812
2018
Q2 		$13K Buy
2,826
+1,576
+126% +$7.15K ﹤0.01% 6439
2018
Q1 		$7K Buy
+1,250
New +$9.03K ﹤0.01% 6742

Other funds holding IPCI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Barclays's IPCI Position: Q4 2018 in Review

Barclays sold out of Intellipharmaceuticals International Inc. (IPCI) in Q4 2018, closing a stake of 1,775 shares — an estimated $5K sold.

Barclays first reported a position in IPCI in Q1 2018 and held it in 3 quarters. The position peaked at $13K in Q2 2018. 12 funds tracked by Wall St. Rank hold IPCI as of Q4 2018.

  • Barclays reported no remaining Intellipharmaceuticals International Inc. position as of Q4 2018 after selling out during the quarter.
  • Barclays sold 1,775 Intellipharmaceuticals International Inc. shares in Q4 2018, an estimated $5K.
  • Barclays first reported a position in Intellipharmaceuticals International Inc. in Q1 2018 and held it in 3 quarters.
  • Barclays's Intellipharmaceuticals International Inc. position peaked at $13K in Q2 2018.
  • 12 funds tracked by Wall St. Rank held Intellipharmaceuticals International Inc. as of Q4 2018.

Based on Barclays's 13F filing for Q4 2018, filed 14 Feb 2019.